

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(10) International Publication Number
WO 2023/110758 A1

(43) International Publication Date
22 June 2023 (22.06.2023)

(51) International Patent Classification:

A61K 47/60 (2017.01) A61P 19/08 (2006.01)
A61P 5/00 (2006.01)

(21) International Application Number:

PCT/EP2022/085414

(22) International Filing Date:

12 December 2022 (12.12.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

21214054.5 13 December 2021 (13.12.2021) EP
22207210.0 14 November 2022 (14.11.2022) EP

(71) Applicant: ASCENDIS PHARMA GROWTH
DISORDERS A/S [DK/DK]; Tuborg Boulevard 12, 2900
Hellerup (DK).

(72) Inventors: SPROGØE, Kennett; c/o Ascendis Pharma
A/S, Tuborg Boulevard 12, 2900 Hellerup (DK). KJEL-
GAARD-HANSEN, Mads Jens; c/o Ascendis Pharma A/
S, Tuborg Boulevard 12, 2900 Hellerup (DK).

(74) Agent: BÜCHEL, Edwin; Patentanwälte Isenbruck Bösl
Hörschler PartG mbB, Seckenheimer Landstraße 4, 68163
Mannheim (DE).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,
KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,
LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG,
NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS,
RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI,
SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: EFFECTIVE DOSES OF CNP CONJUGATES

(57) Abstract: The present invention relates to unit dosage forms comprising a CNP conjugate or pharmaceutically acceptable salt thereof.

WO 2023/110758 A1